Drugs / U3 1565
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01290471 | Jan 2011 → Jan 2013 | ovarian carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U3 1565 | “This is a Phase 1, open label study to assess the safety and tolerability of U3 1565, determine maximum tolerated dose (MTD) or establish maximum administered dose (MAD) safety...” NCT01290471 ↗ |
| Route | Intravenous | “administered by continuous IV infusion over 60 minutes” NCT01290471 ↗ |